Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study
- 12 September 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117041
Abstract
No abstract availableKeywords
Funding Information
- MSD Sharp and Dohme
- Merck
- Orion Corporation
- Merck Sharp and Dohme United Kingdom
This publication has 34 references indexed in Scilit:
- Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)European Urology, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Current therapy and drug resistance in metastatic castration-resistant prostate cancerDrug Resistance Updates, 2023
- Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agentsAnnals of Oncology, 2023
- Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022European Journal of Cancer, 2023
- ESR1 activating mutations: From structure to clinical applicationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate CancerEuropean Urology, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working GroupEuropean Journal of Cancer, 2016
- Use of Glucocorticoids and Risk of Venous ThromboembolismJAMA Internal Medicine, 2013